Eisai gives up on sibutramine in Japan
This article was originally published in Scrip
Eisai has withdrawn a Japanese approval application for the obesity drug sibutramine, following originator Abbott's decision to pull the product from several major markets.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.